Danish pharmaceutical company Novo Nordisk (NVO) has teamed up with artificial intelligence (AI) leader Anthropic to leverage frontier AI models, including Claude Science, to supercharge its drug discovery and research and development (R&D) operations.
The collaboration aims to address complex biological challenges, streamline software engineering, and compress the timelines required to bring treatments for chronic diseases to market.
